IL-33 inhibits cardiac hypertrophy caused by AngII through activating NF-κB, and as a decoy receptor of IL-33, the serum expression of sST2 increases in patients with myocardial hypertrophy and heart failure caused by it [62], and the expression was correlated with the grade of heart failure. Here, AGT is linked to cardiac hypertrophy.